Goldman Sachs’s Intersect ENT, Inc XENT Stock Holding History

Goldman Sachs’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-70,000	Closed	-$1.96M	–	6953
2017 Q2	$1.96M	Hold	70,000	–	–	﹤0.01%	3858
2017 Q1	$1.2M	Hold	70,000	–	–	﹤0.01%	4218
2016 Q4	$847K	Buy	70,000 +2,500	+4%	+$32.4K	﹤0.01%	4594
2016 Q3	$1.07M	Buy	+67,500	New	+$1.02M	﹤0.01%	4340
2016 Q1	–	Sell	-50,000	Closed	-$1.13M	–	7402
2015 Q4	$1.13M	Buy	+50,000	New	+$989K	﹤0.01%	4183

Goldman Sachs's XENT Position: Q2 2022 in Review

Goldman Sachs sold out of Intersect ENT, Inc (XENT) in Q2 2022, closing a stake of 742,905 shares — an estimated $20.8M sold.

Goldman Sachs first reported a position in XENT in Q3 2014 and held it in 28 quarters. The position peaked at $20.8M in Q1 2022. 0 funds tracked by Wall St. Rank hold XENT as of Q2 2022.

Goldman Sachs reported no remaining Intersect ENT, Inc position as of Q2 2022 after selling out during the quarter.
Goldman Sachs sold 742,905 Intersect ENT, Inc shares in Q2 2022, an estimated $20.8M.
Goldman Sachs first reported a position in Intersect ENT, Inc in Q3 2014 and held it in 28 quarters.
Goldman Sachs's Intersect ENT, Inc position peaked at $20.8M in Q1 2022.
0 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q2 2022.

Based on Goldman Sachs's 13F filing for Q2 2022, filed 15 Aug 2022.